Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office
2.12.2025 14:00:00 CET | Business Wire | Press Release
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/
LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE
As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment.
“With this Series C raise and the upcoming build-out of global compute infrastructure, we have the capital and capacity to bring world-scale AI to creatives everywhere,” said Amit Jain, CEO and co-founder of Luma AI. “Launching across EMEA is the logical next step in putting this power directly in the hands of storytellers, agencies, and brands globally.”
Luma AI expects to create 200 roles in London in 2026, across research, engineering, partnerships, and strategic development. By 2028, the company expects to significantly add roles across the UK, Europe, and Saudi Arabia as new workflows emerge in advertising, brands, and entertainment.
Jason Day Joins Luma AI as Head of EMEA
Jason Day, formerly Executive Vice President of Global Growth at Monks, will lead international business development, strategic partnerships, and customer expansion outside the United States. He brings more than 15 years of experience building global client relationships and scaling creative and technology teams across Europe, the Middle East, Africa, and Asia.
Before joining Monks, Day held senior roles at WPP - including Global Business Director and Director for WPP-Scangroup - and holds an MBA from the University of Oxford’s Said Business School. His background in operational excellence, P&L leadership, and talent development gives Luma AI a strong foundation for responsible growth in new markets.
“Jason brings a rare combination of commercial strategy, international growth experience, and deep understanding of the creative space,” said Caroline Ingeborn, COO of Luma AI. “His leadership across Monks and WPP - especially scaling large cross-border teams and building client relationships in markets like London. Munich and Riyadh make him the ideal leader to drive our next chapter. With Jason leading from London, Luma AI can bring creative intelligence directly into the hands of marketers and storytellers around the world.”
Day added: “Luma AI is the world leader in developing multimodal artificial generative intelligence (AGI) for the creative industry. Putting that intelligence into the hands of creative professionals around the world - be they marketers, gamers, or film studios - will transform the entire creative process. The regions we are expanding into are actively building new creative economies, with a need for technology that accelerates production without compromising quality. The potential for creative intelligence is still largely untapped, and this is the moment to scale it across industries and geographies.”
The expansion follows Luma AI’s recently announced $900 million Series C funding round. As part of the partnership, Luma AI will partner with HUMAIN on Project Halo - a 2-gigawatt supercluster designed to power large-scale AI systems to train and deploy large-scale multimodal World Models to build systems for AI-assisted production, simulation, education, design, and advertising.
About Luma AI
Luma AI is building a multimodal general intelligence that can generate, understand, and operate in the physical world. Its flagship platform, Dream Machine, enables creatives everywhere to generate professional-grade video and images. In 2025, Luma released Ray3, the world’s first reasoning video model capable of creating physically accurate videos, animations, and visuals. Luma’s models are utilized by top entertainment studios, ad agencies, and technology leaders, including Adobe and AWS, and are available via subscription or API. The company is backed by HUMAIN, Andreessen Horowitz, AWS, AMD Ventures, NVIDIA, Amplify Partners, Matrix Partners, and angels from across the technology and entertainment space. For more information, visit www.lumalabs.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202217704/en/
Contacts
Peter Binazeski
Head of Communications
Luma AI
peter@lumalabs.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom